[
  {
    "symbol": "MDGL",
    "price": 221.68,
    "beta": -0.705281,
    "volAvg": 367562,
    "mktCap": 4054349856,
    "lastDiv": 0,
    "range": "57.21-322.67",
    "changes": 17.8,
    "companyName": "Madrigal Pharmaceuticals, Inc.",
    "currency": "USD",
    "cik": "0001157601",
    "isin": "US5588681057",
    "cusip": "558868105",
    "exchange": "NASDAQ Global Select",
    "exchangeShortName": "NASDAQ",
    "industry": "Biotechnology",
    "website": "https://www.madrigalpharma.com",
    "description": "Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ÃŸ agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.",
    "ceo": "Dr. Paul A. Friedman M.D.",
    "sector": "Healthcare",
    "country": "US",
    "fullTimeEmployees": "92",
    "phone": "267 824 2827",
    "address": "Four Tower Bridge",
    "city": "West Conshohocken",
    "state": "PA",
    "zip": "19428",
    "dcfDiff": 220.727,
    "dcf": 68.7734,
    "image": "https://financialmodelingprep.com/image-stock/MDGL.png",
    "ipoDate": "2007-02-06",
    "defaultImage": false,
    "isEtf": false,
    "isActivelyTrading": true,
    "isAdr": false,
    "isFund": false
  }
]